FDA Accepts PMA Application for Augment Bone Graft
BioMimetic Therapeutics Inc announced that the US Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the US. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company added.
-
Smaller size of Medtronic INFUSE Bone Graft approved
European Edition Of SAGE Foot and Ankle Specialist To Launch
Osteotech receives FDA nod for Plexur P
Fracture Risk Assessment Tool Now Available As An iPhone Application
Enobia Provides Update On Progress With ENB-0040, A Bone-Targeted Enzyme Replacement Therapy For Hypophosphatasia
